Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEHAWNASDAQ:ATNFWNASDAQ:LBPSWNYSE:NVO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEHAWAesther Healthcare Acquisition$0.01$0.01$0.06▼$0.33N/AN/A34,287 shsN/AATNFW180 Life Sciences$0.01-4.8%$0.01$0.00▼$0.04N/AN/A97,681 shs9,714 shsLBPSW4D pharma$0.00$0.04▼$1.29N/AN/A20,931 shsN/ANVONovo Nordisk A/S$68.50+1.2%$69.11$57.00▼$145.99$305.85B0.667.24 million shs5.62 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEHAWAesther Healthcare Acquisition0.00%0.00%-28.57%-56.52%-75.06%ATNFW180 Life Sciences0.00%-8.05%0.00%0.00%-21.57%LBPSW4D pharma0.00%0.00%0.00%0.00%0.00%NVONovo Nordisk A/S0.00%-7.13%-4.06%-1.55%-52.01%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ALBPSW4D pharmaN/AN/AN/AN/AN/AN/AN/AN/ANVONovo Nordisk A/S4.6678 of 5 stars4.15.02.50.02.30.03.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEHAWAesther Healthcare Acquisition 0.00N/AN/AN/AATNFW180 Life Sciences 0.00N/AN/AN/ALBPSW4D pharma 0.00N/AN/AN/ANVONovo Nordisk A/S 2.27Hold$112.0063.50% UpsideCurrent Analyst Ratings BreakdownLatest NVO, ATNFW, LBPSW, and AEHAW Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/28/2025NVONovo Nordisk A/SHsbc Global ResSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/25/2025NVONovo Nordisk A/SDbs BankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeSell4/17/2025NVONovo Nordisk A/SGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/17/2025NVONovo Nordisk A/SBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$105.00 ➝ $64.004/15/2025NVONovo Nordisk A/SBNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageStrong-Buy ➝ Underperform(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/AN/AN/AN/AN/ALBPSW4D pharma$522KN/AN/AN/AN/AN/ANVONovo Nordisk A/S$42.12B7.26$3.90 per share17.56$4.66 per share14.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEHAWAesther Healthcare AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/A0.00∞N/AN/AN/AN/AN/ALBPSW4D pharmaN/AN/A0.00N/AN/AN/AN/AN/AN/ANVONovo Nordisk A/S$14.64B$3.3820.2714.701.2234.52%80.94%24.23%8/6/2025 (Estimated)Latest NVO, ATNFW, LBPSW, and AEHAW EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025NVONovo Nordisk A/S$0.92$0.92N/A$0.92N/A$11.87 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/AN/AN/AN/ALBPSW4D pharmaN/AN/AN/AN/AN/ANVONovo Nordisk A/S$1.642.39%N/A48.52%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEHAWAesther Healthcare AcquisitionN/AN/AN/AATNFW180 Life SciencesN/AN/AN/ALBPSW4D pharmaN/AN/AN/ANVONovo Nordisk A/S0.700.740.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEHAWAesther Healthcare AcquisitionN/AATNFW180 Life SciencesN/ALBPSW4D pharmaN/ANVONovo Nordisk A/S11.54%Insider OwnershipCompanyInsider OwnershipAEHAWAesther Healthcare AcquisitionN/AATNFW180 Life SciencesN/ALBPSW4D pharmaN/ANVONovo Nordisk A/S0.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEHAWAesther Healthcare Acquisition2N/AN/ANot OptionableATNFW180 Life Sciences7N/AN/ANot OptionableLBPSW4D pharmaN/AN/AN/ANot OptionableNVONovo Nordisk A/S77,3494.47 billion4.46 billionOptionableNVO, ATNFW, LBPSW, and AEHAW HeadlinesRecent News About These Companies7 Killer European Stocks To Buy In JulyJune 29 at 10:52 AM | 247wallst.com3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking (NVO)...June 29 at 8:36 AM | marketbeat.comMmbg Investment Advisors CO. Purchases 12,320 Shares of Novo Nordisk A/S (NYSE:NVO)June 29 at 7:47 AM | marketbeat.comNovo Nordisk A/S (NYSE:NVO) Shares Sold by Naviter Wealth LLCJune 29 at 7:24 AM | marketbeat.comSovran Advisors LLC Makes New Investment in Novo Nordisk A/S (NYSE:NVO)June 29 at 6:41 AM | marketbeat.comNovo Nordisk (NVO) Partners with WeightWatchers After Hims & Hers FalloutJune 29 at 2:27 AM | theglobeandmail.comNovo Nordisk (NVO) Terminates Hims & Hers Partnership Over Wegovy Sales IssuesJune 28 at 6:30 AM | msn.comCarolina Wealth Advisors LLC Purchases 8,378 Shares of Novo Nordisk A/S (NYSE:NVO)June 28 at 5:44 AM | marketbeat.comMirae Asset Global Investments Co. Ltd. Increases Stock Position in Novo Nordisk A/S (NYSE:NVO)June 28 at 5:35 AM | marketbeat.comBartlett & CO. Wealth Management LLC Cuts Stock Position in Novo Nordisk A/S (NYSE:NVO)June 28 at 5:17 AM | marketbeat.comNovo Nordisk Just Announced WeightWatchers Will Sell WegovyJune 27 at 8:26 PM | inc.com6 International Stocks To buy in JulyJune 27 at 3:36 PM | 247wallst.comNovo Nordisk A/S (NYSE:NVO) Trading 1.5% Higher - What's Next?June 27 at 1:39 PM | marketbeat.comNVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?June 27 at 12:11 PM | zacks.comLoring Wolcott & Coolidge Fiduciary Advisors LLP MA Has $8.40 Million Stake in Novo Nordisk A/S (NYSE:NVO)June 27 at 7:15 AM | marketbeat.comHealth Rounds: Novo Nordisk's semaglutide may help some with type 1 diabetesJune 27 at 7:08 AM | reuters.comNVO Novo Nordisk A/S - Seeking AlphaJune 26, 2025 | seekingalpha.comNovo Nordisk’s Mim8 Shows Strong Tolerability, Patient Preference in Hemophilia AJune 26, 2025 | pharmexec.comPNovo Nordisk ends Hims & Hers deal over Wegovy knockoffsJune 26, 2025 | njbiz.comNNovo Nordisk inks partnership with WeightWatchers to broaden Wegovy accessJune 26, 2025 | fiercehealthcare.comFNovo Nordisk to Expand Access to Wegovy with WeightWatchers PartnershipJune 26, 2025 | wsj.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeRKLB Breakout Fails Near Highs: Should Investors Be Concerned?By Ryan Hasson | June 11, 2025View RKLB Breakout Fails Near Highs: Should Investors Be Concerned?With Novo Nordisk's CEO Out, Wall Street Wants an American LeaderBy Leo Miller | June 7, 2025View With Novo Nordisk's CEO Out, Wall Street Wants an American LeaderNVO, ATNFW, LBPSW, and AEHAW Company DescriptionsAesther Healthcare Acquisition NASDAQ:AEHAW$0.01 0.00 (0.00%) As of 06/27/2025Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.180 Life Sciences NASDAQ:ATNFW$0.0080 0.00 (-4.76%) As of 06/27/2025 03:55 PM Eastern180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.4D pharma NASDAQ:LBPSW4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.Novo Nordisk A/S NYSE:NVO$68.50 +0.80 (+1.18%) Closing price 06/27/2025 03:59 PM EasternExtended Trading$68.47 -0.03 (-0.04%) As of 06/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
